Pay in 4 interest-free payments of $5.04 Learn more
Ships within 48 hours · Estimated delivery Oct 9 - Oct 14
discontinued CJC-1295 (DAC) Not FDA-approved Feature Phase III Trial Data Tesamorelin Yes (n=816 pooled) Sermorelin No adult Phase III VAT datasets CJC-1295 (DAC) No Feature Visceral Fat Reduction Tesamorelin 15-20% at 26 weeks Sermorelin Not formally studied in RCTs CJC-1295 (DAC) Not formally studied in RCTs Feature Liver Fat Reduction Tesamorelin 32% at 12 months (NAFLD trial) Sermorelin Not studied CJC-1295 (DAC) Not studied Feature Typical Research Dose Tesamorelin 2 mg daily Sermorelin 200-300 mcg nightly CJC-1295 (DAC) 1-2 mg weekly Feature Unique Advantage Tesamorelin Only FDA-approved GHRH with deepest trial evidence Sermorelin Longest historical track record CJC-1295 (DAC) Weekly dosing convenience Tesamorelin is the only GHRH peptide with active FDA approval and validated Phase III visceral-fat data
Medications are 99%+ purity tested and HSA/FSA eligible
Alvarez, X
No other mineral and vitamin supplements are needed if your equine companion is taking Omneity Pellets daily
Retail without any discount: $900 to $1,640
US$ 21.30
US$ 27.68
US$ 25.14
US$ 159500.00
Sold : Login>>
